Product Catalog [{"id":"64","name":"Cyramza","price":2364,"sku":"Cyramza (ramucirumab)","brand":"Lilly","position":1,"category":"Diseases\/Oncology\/Colorectal Cancer"},{"id":"32","name":"Lonsurf","price":813.96,"sku":"Lonsurf (trifluridine\/tipiracil)","brand":"Les Laboratoires Servier","position":2,"category":"Diseases\/Oncology\/Colorectal Cancer"},{"id":"21","name":"Opdivo","price":497.04,"sku":"Opdivo (nivolumab)","brand":"Bristol-Myers Squibb Pharma EEIG","position":3,"category":"Diseases\/Oncology\/Colorectal Cancer"}]

Colorectal Cancer

Globally, colorectal cancer is the third most common type of cancer making up about 10% of all cancer cases. In 2012 there were 1.4 million new cases and 694,000 deaths from colorectal cancer1. The 5-year survival rates in the United States are around 65%.

Colorectal cancer typically starts with a benign tumour

Colorectal cancer typically starts with a benign tumour, often in the form of a polyp, which over time becomes cancerous1. Treatment options are depending on the stage of the disease, overall health and preferences of the patient2. Standard treatments include surgery, chemotherapy, radiotherapy or a combination3.


1. Colorectal cancer,
    Wikipedia, last edited January 2018

2. Current standards and new trends in the primary treatment of colorectal cancer
    Stein, Alexander et al., European Journal of Cancer , Volume 47 , S312 - S314, Sep. 2011

3. Colon Cancer Treatment (PDQ®) – Patient Version,
    National Cancer Institute, updated December 2017

  1. Cyramza
  2. Lonsurf
    Lonsurf (trifluridine/tipiracil)
    Colorectal Cancer
  3. Opdivo
    Opdivo (Nivolumab)
    Urothelial Carcinoma, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Lymphoma, Skin Cancer
View as Grid List

3 Items

per page
Set Descending Direction